1.21
-0.11(-8.33%)
Currency In USD
| Previous Close | 1.32 |
| Open | 1.31 |
| Day High | 1.3 |
| Day Low | 1.21 |
| 52-Week High | 5.92 |
| 52-Week Low | 0.66 |
| Volume | 1.33M |
| Average Volume | 2.03M |
| Market Cap | 138.71M |
| PE | -0.81 |
| EPS | -1.49 |
| Moving Average 50 Days | 1.06 |
| Moving Average 200 Days | 2.02 |
| Change | -0.11 |
If you invested $1000 in Fate Therapeutics, Inc. (FATE) 10 years ago, it would be worth $201.33 as of June 01, 2025 at a share price of $1.21. Whereas If you bought $1000 worth of Fate Therapeutics, Inc. (FATE) shares 5 years ago, it would be worth $38.19 as of June 01, 2025 at a share price of $1.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
GlobeNewswire Inc.
May 30, 2025 8:30 PM GMT
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies t
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
GlobeNewswire Inc.
May 28, 2025 9:54 PM GMT
Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE)SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics,
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
GlobeNewswire Inc.
Apr 29, 2025 1:25 PM GMT
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indicationsSAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Fate Therapeuti